Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 11.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 66,645 shares of the medical equipment provider's stock after buying an additional 6,769 shares during the quarter. Texas Permanent School Fund Corp owned 0.10% of Lantheus worth $5,351,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of LNTH. Vanguard Group Inc. raised its stake in shares of Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock valued at $458,271,000 after buying an additional 389,828 shares in the last quarter. Westfield Capital Management Co. LP boosted its holdings in shares of Lantheus by 25.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock valued at $121,867,000 after buying an additional 394,837 shares during the period. Farallon Capital Management LLC boosted its stake in Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock worth $92,316,000 after purchasing an additional 1,269,900 shares during the period. Reinhart Partners LLC. raised its position in Lantheus by 8.4% in the 1st quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider's stock valued at $91,517,000 after buying an additional 114,110 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Lantheus by 0.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider's stock worth $52,077,000 after purchasing an additional 7,590 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company's stock.

Analyst Ratings Changes

LNTH has been the subject of a number of recent research reports. JMP Securities lowered their price objective on Lantheus from $130.00 to $125.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 1st. Truist Financial decreased their price objective on Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. Leerink Partners upped their price target on Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a research report on Thursday, July 11th. Redburn Atlantic started coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a "buy" rating and a $175.00 price objective for the company. Finally, B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $126.00.

Insider Transactions at Lantheus

In related news, Director Gerard Ber sold 15,500 shares of the business's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now owns 21,221 shares in the company, valued at $2,047,402.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CAO Andrea Sabens sold 341 shares of the company's stock in a transaction on Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares of the company's stock, valued at $7,661,900.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gerard Ber sold 15,500 shares of the company's stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,852 shares of company stock worth $3,922,001. 1.50% of the stock is currently owned by insiders.

Lantheus Stock Performance

LNTH traded up $1.52 during midday trading on Friday, hitting $105.55. 1,058,194 shares of the company traded hands, compared to its average volume of 1,028,340. The firm has a market capitalization of $7.33 billion, a PE ratio of 16.11 and a beta of 0.50. The company's 50-day moving average is $104.37 and its 200 day moving average is $82.38. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share for the quarter, missing the consensus estimate of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to the consensus estimate of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The company's quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the prior year, the company posted $1.40 EPS. On average, research analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.